The Effects of Intravitreal Agents on Systemic Vascular Diseases in Patients with Diabetic Retinopathy

Sedat Ozmen (✉ drsozmen@gmail.com)  
sakarya university education and research hospital

bürüncakır  
Sakarya University Faculty of Medicine: Sakarya Universitesi Tip Fakultesi

nilgünözkanaksoy  
Sakarya University Faculty of Medicine: Sakarya Universitesi Tip Fakultesi

erkançelik  
Sakarya University Faculty of Medicine: Sakarya Universitesi Tip Fakultesi

yüşimgüzeyaras  
Sakarya University Faculty of Medicine: Sakarya Universitesi Tip Fakultesi

kahramancoşansu  
Sakarya University Faculty of Medicine: Sakarya Universitesi Tip Fakultesi

Research Article

Keywords: Diabetic Retinopathy, Anti Vegf, Cerebrovascular deseases, Coronary artery disease.

Posted Date: December 29th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1208757/v1

License: ☭ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Purpose:** To assess the risk for cerebrovascular disease (CVD) and coronary artery disease (CAD) in diabetic patients who were treated with intravitreal anti-VEGF agents and compare the rates of CVD and CAD with diabetic controls.

**Methods:** A retrospective chart review of diabetic patients was performed. The need for intravitreal injection and type of agent were noted. If clinically significant or center-involving diabetic macular edema (DME) were determined, intravitreal anti-VEGF agents were used. The CVD and/or CAD occurred within 6 months of the intravitreal injection were accepted as the main outcomes of the study. The records of diabetic patients who were followed up but not needed intravitreal injections were accepted as the control group of the study. Comparisons between these groups were performed.

**Results:** The number of patients enrolled in the study was 9751 (5243 female, 4508 male patients). Of these patients, 1261 patients were received various intravitreal injections. Patients who had CVD history were divided into two groups according to whether they received intravitreal injection or not. There was statistically significant difference between these groups in terms of CVD history (p<0.001). There was statistically significant difference in the hazard of CVD between different anti-VEGF treatments (p<0.001). Patients who had CAD history were divided into two groups according to whether they received intravitreal injection or not. There was no statistically significant difference between these groups in terms of CAD history (p=0.31).

**Discussion:** The risk for CVD was seen to increase with the intravitreal anti-VEGF treatment in diabetic patients. The rate of CVD was higher in patients who received intravitreal bevacizumab treatment.

Introduction

Diabetic retinopathy (DR) is the most common complication of diabetes and is expected that 642 million people will suffer from DR by 2040 [1]. The most common cause of visual impairment due to DR is diabetic macular edema (DME)[2]. The intravitreal administration of anti-vascular endothelial growth factors (VEGF) is commonly used for the treatment of center-involving DME with decreased vision [3]. Two mg every 8 weeks after 5 initial monthly injections of aflibercept and 0.3 mg monthly injection of ranibizumab were approved by US Food and Drug Administration based on VIVID-VISTA and RISE-RIDE clinical trials results, respectively [4, 5]. Off-label use of 1,25 mg intravitreal bevacizumab is also common all over the World [6]. Besides, intravitreal administrations of anti-VEGF agents have been used for proliferative DR [7].

The frequency of intravitreal injections of anti-VEGF agents in diabetic patients has been increased because of the expanding indications. While the increasing rates of intravitreal anti-VEGF injections, the ocular and systemic complications of such a widely performed procedure have been commonly reported [8–10]. Systemic side effects and overall mortality due to anti-VEGF agents were not found to be increased in the short and medium term when compared with either sham group or photocoagulation
treatment in patients with DME [11]. Besides, adverse systemic diseases in patients with proliferative DR were not found to be different when compared with controls [8]. On the other hand, a recent meta-analysis that focused on the patients which had highest-level exposure to anti-VEGF agents, revealed a possible increased risk of death and cerebrovascular accidents. In the same meta-analysis report, no increased risk of myocardial infarction was detected [10].

The aim of the current study was to assess the risk for cerebrovascular diseases (CVD) and coronary artery disease (CAD) in diabetic patients who were treated with intravitreal anti-VEGF agents and compare the rates of CVD and CAD with diabetic controls.

Materials-methods

The present, retrospective study was conducted in a tertiary university hospital. Prior approval from the Institutional Review Board was taken (IRB number: E-71522473-050.01.04-6071-49 and informed consent was obtained from each subject. The study was performed in adherence to the Declaration of Helsinki.

A retrospective chart review of diabetic patients at the Retinal Disease Department was performed. The chart reviews included medical records between January 2010 and December 2020. The age, sex, serum HbA1c levels, and duration of diabetes mellitus of patients were noted. The need for intravitreal injection and type of agent were also noted. The stage of diabetic retinopathy was noted as proliferative and non-proliferative DR. If clinically significant or center-involving DME were determined, intravitreal anti-VEGF agents were used. The preference of anti-VEGF agent was done according to ophthalmologist decision. The diagnosis of clinically significant DME was done due to ETDRS [12]. Center-involving DME was defined as thickening of the retina at or within 500 μ of the center of the macula [13].

The histories of CVD or CAD in patients after intravitreal injections were noted. The CVD and/or CAD occurred within 6 months of the intravitreal injection were accepted as the main outcomes of the study. The records of diabetic patients who were followed up in Retina Department but not needed intravitreal injections were accepted as the control group of the study. The histories of CVD and CAD in these patients were also noted.

Cerebrovascular diseases were composed of ischemic stroke and hemorrhagic stroke. Coronary artery diseases were composed of myocardial infarction and unstable angina.

Patients with the age below 18 years old, any intraocular surgeries, chronic ocular diseases such as uveitis, glaucoma were excluded from the study. Patients with other retinal diseases such as age related macular degeneration, santral, branch retinal vein occlusion, and choroidal neovascularization.

Statistical analysis was performed by using SPSS statistical software (IBM SPSS Statistics, Version 23.0. Armonk, NY: IBM Corp.) Descriptive analyses were performed to provide information on the general characteristics of the study population. Kolmogorov-Smirnov test was used to evaluate whether the
distributions of numerical variables were normal. The numeric variables were presented as mean ± standard deviation. Categorical variables were compared by the Chi-Square test. A p-value <0.05 was considered significant.

Results

The number of patients enrolled in the study was 9751 (5243 female, 4508 male patients). The mean age was 65.2 ± 11.0 years. The mean HbA1c was 7.6 ± 1.1 mmol/l. Of these patients, 1261 patients were received various intravitreal injections because of DME with or without proliferative DR. Of these patients, 855 was diagnosed as CSME and 406 was diagnosed as center-involving DME. (Table 1).

Table 2 reveals the number of patients who had CVD. 25 patients had a diagnosis of ischemic CVD and 1 patient had hemorrhagic CVD diagnosis. Patients who had CVD history were divided into two groups according to whether they received intravitreal injection or not. There was statistically significant difference between these groups in terms of CVD history (p<0.001).

Table 3 reveals the number of patients who had CAD. All patients underwent coronary angiography and coronary stenosis implantation was performed 28 patients, coronary bypass grafting performed 2 patients. Patients who had CAD history were divided into two groups according to whether they received intravitreal injection or not, again. There was no statistically significant difference between these groups in terms of CAD history (p=0.31).

The possible effect of different anti-VEGF treatment modalities on CVD was also assessed. There was statistically significant difference in the hazard of CVD between different anti-VEGF treatments (p<0.001) (Table 4).

The possible effect of different anti-VEGF treatment modalities on CAD was also assessed and no statistically significant difference was found in the hazard of CVD between different anti-VEGF treatments (p=0.84) (Table 5).
Table 1
Number of diabetic patients who received various intravitreal agent treatments.

| Treatment | Frequency (n) | Percent (%) |
|-----------|--------------|-------------|
| No Intravitreal Agent Use | 8490 | 87,1 |
| Bevacizumab treatment | 179 | 1,8 |
| Ranibizumab treatment | 455 | 4,7 |
| Afibercept treatment | 364 | 3,7 |
| Bevacizumab+Ranibizumab Treatment | 139 | 1,4 |
| Bevacizumab+afibercept treatment | 44 | 0,5 |
| Ranibizumab+Afibercept Treatment | 66 | 0,7 |
| Bevacizumab+Ranibizumab+Afibercept treatment | 14 | 0,1 |
| Total | 9751 | 100 |

Table 2
The number of patients who had cerebrovascular disease history

| CVD history (n) | No CVD history (n) | Percent |
|----------------|--------------------|---------|
| No intravitreal treatment | 8423 | 67 | 0,8 |
| Intravitreal treatment | 1235 | 26 | 2,1 |

CVD: cerebrovascular disease. According to Chi-square test, there was significant difference between these groups. p<0,001.

Table 3
The number of patients who had coronary artery disease history

| CAD history (n) | No CAD history (n) | Percent |
|----------------|--------------------|---------|
| No intravitreal treatment | 8242 | 248 | 2,9 |
| Intravitreal treatment | 1228 | 33 | 2,6 |

CAD: coronary artery disease. According to Chi-square test, there was no significant difference between these groups. p=0,310.
Table 4  
Cerebrovascular disease in patients who were received different treatment modalities

| Treatment                          | No CVD history (n) | CVD history (n) | Percent (%) |
|------------------------------------|-------------------|-----------------|-------------|
| No intravitreal treatment          | 8422              | 67              | 0.8         |
| Bevacizumab treatment              | 171               | 8               | 4.5         |
| Ranibizumab treatment              | 443               | 12              | 2.6         |
| Aflibercept treatment              | 360               | 4               | 1.1         |
| Bevacizumab+Ranibizumab treatment  | 137               | 2               | 1.4         |
| Bevacizumab+Aflibercept treatment  | 44                | 0               | 0           |
| Ranibizumab+Aflibercept treatment  | 66                | 0               | 0           |
| Bevacizumab+Ranibizumab+Aflibercept treatment | 14         | 0               | 0           |

CVD: cerebrovascular disease. According to Chi-square test, there was statistically significant difference among groups (p<0.001).
Table 5  
Coronary artery diseases in patients who were received different treatment modalities

| Treatment                                      | No CAD history (n) | CAD history(n) | Percent (%) |
|------------------------------------------------|-------------------|----------------|-------------|
| No intravitreal treatment                      | 8242              | 247            | 2.9         |
| Bevacizumab treatment                          | 173               | 6              | 3.4         |
| Ranibizumab treatment                          | 441               | 14             | 3.1         |
| Aflibercept treatment                          | 353               | 11             | 3           |
| Bevacizumab+Ranibizumab Treatment              | 137               | 2              | 1.4         |
| Bevacizumab+aflibercept treatment              | 44                | 0              | 0           |
| Ranibizumab+Aflibercept Treatment              | 65                | 1              | 1.5         |
| Bevacizumab+Ranibizumab+Aflibercept treatment  | 14                | 0              | 0           |

CAD: Coronary artery disease. According to Chi-square test, there was no statistically significant difference among groups (p=0.84).

Discussion

In the current study, the rate of CVD was higher in diabetic patients who had treated with anti-VEGF agents than diabetic controls. The percentage of patients who had CVDs was 2.1%. Wu et al. was reported that CVDs were seen in 0.5% percent of patients who received intravitreal Bevacizumab treatment. The diagnosis of patients were variable in this study [14]. In a recent meta-analysis, possible increased risk for cerebrovascular accidents was revealed in patients with DME who were treated with intravitreal anti-VEGF agents for 2 years [10]. In our study, the control group was composed of diabetic patients. As reported previously that the risk for cerebrovascular deseases (stroke) was higher in diabetic patients, the comparison between diabetics who received intravitreal anti-VEGF treatment and diabetic controls gave us more accurate results [15]. Maloney et al. compared CVD between diabetic patients who received anti-VEGF agents, argon laser treatment, and steroid treatment. They did not find any increased risk of cerebrovascular diseases within 6 months after intravitreal anti-VEGF treatment. In this study, the cerebrovascular diseases were consisted of ischemic, hemorrhagic stroke and transient ischemic attack [2]. In our study, we investigated only ischemic and hemorrhagic stroke.

In the current study, the risk of CVD was found to be higher in diabetic patients who were treated with intravitreal Bevacizumab. Maloney et al. compared the risk of cerebrovascular diseases after intravitreal bevacizumab, ranibizumab, and aflibercept treatments in diabetic patients. They did not find any
difference among different intravitreal anti-VEGF agents [16]. Cerebrovascular diseases were composed of hemorrhagic, ischemic stroke and transient ischemic attack. Wang et al. compared the incidence of systemic adverse diseases of intravitreal bevacizumab and ranibizumab in patients with age related macular degeneration. They did not find any difference [17]. The severity of diabetes mellitus, the differences in the inclusion criteria and investigation on different retinal diseases might cause variety in the results.

In this current study, the risk of coronary artery diseases after intravitreal anti-VEGF treatment did not increase. In a recent meta-analysis, 24 clinical trials were included which were investigated major cardiovascular diseases in diabetic patients. They did not find any difference in diabetic patients in regards of cardiovascular diseases [18]. In another meta-analysis, ranibizumab and aflibercept treatments were found to not affect the risk for myocardial infarction and arteriotoxic diseases [10]. Maloney et al. also did not find any increased risk for CAD in diabetic patients treated with intravitreal anti-VEGF agents [2]. All these studies and our study revealed no increased risk for CAD in diabetic patients treated with anti-VEGF agents.

In this study, different types of anti-VEGF agents were also investigated whether they affect the risk for CAD. There was no significant difference between ranibizumab, bevacizumab and aflibercept treatments. Maloney et al. also did not find any increased risk for acute myocardial infarction and cardiovascular diseases with all these treatments [16].

The limitation of this current study was the numeric differences between groups. the retrospective design did not allow us to reach more information about the treatment of diabetic controls. On the other hand, to investigate only one disease (Diabetes Mellitus) treated with intravitreal agents gave us more accurate and reliable results.

In conclusion, the risk for cerebrovascular diseases was increased with the intravitreal anti-VEGF treatment in diabetic patients. The rate of CVD was higher in diabetic patients who received intravitreal bevacizumab treatment. On the other hand, the risk for coronary artery disease did not affect from intravitreal anti-VEGF treatment in diabetic patients.

**Statements and Declarations:**

**Declarations**

**Funding**: This study was not funded by any company.

**Compliance with ethical standards**: Conflict of interest All authors declare that they have no conflict of interest.

**Ethical standard**: Prior approval from the Sakarya University Institutional Review Board IRB: 71522473-050.01.04-6071-49 was taken. The study was performed in adherence to the 1964 Declaration of Helsinki.
Informed consent: Written informed consent was obtained from the parents of each subject in the study.

References

1. Simó-Servat O, Hernández C, Simó R. (2019) Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Res;62:211–217. https://doi.org/10.1159/000499541

2. Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. (2019) Risk of Systemic Adverse Deseases Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology;126(7):1007–1015. https://doi.org/10.1016/j.jophtha.2018.09.040

3. Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. (2020) Intern Emerg Med.;15(2):199–210. https://doi.org/10.1007/s11739-019-02253-7

4. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffé GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. (2016) Ophthalmology;123(11):2376-2385. https://doi.org/10.1016/j.jophtha.2016.07.032

5. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology;119(4):789–801. https://doi.org/10.1016/j.jophtha.2011.12.039

6. Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 123(6):1351–1359. https://doi.org/10.1016/j.jophtha.2016.02.022

7. Sun JK, Jampol LM. (2019) The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy. Ophthalmic Res;62(4):225–230. https://doi.org/10.1159/000502779

8. Simunovic MP, MBBCChir, PhD FRANZCO, Maberley DAL, MSc MD (2015) Anti-Vascular endothelial growth factor therapy for proliferative diabetic retinopathy, Retina: Volume 35 - Issue 10 - p 1931–1942 https://doi.org/10.1097/IAE.0000000000000723

9. Shikari H, Silva PS, Sun JK. (2014) Complications of intravitreal injections in patients with diabetes. Semin Ophthalmol 29(5-6):276–289. https://doi.org/10.3109/08820538.2014.962167

10. Avery RL, Gordon GM (2016) Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. JAMA Ophthalmol 134(1):21–29. https://doi.org/10.1001/jamaophthalmol.2015.4070

11. Virgili G, Parravano M, Menchini F, Evans JR. (2014) Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev.;(10):CD007419. doi: 10.1002/14651858.CD007419.pub4
12. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study group. (1985) Archives of Ophthalmology; 103(12):1796–1806. https://doi.org/10.1001/archopht.1985.01050120030015

13. Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, Augustin A, de Smet MD, Chhablani J, Tufail A, García-Layana A, Sudhalkar A, Mathis T. (2019) First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol; 29(6):573–584. https://doi.org/10.1177/1120672119857511

14. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodríguez FJ (2008) Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81–87. https://doi.org/10.1007/s00417-007-0660-z

15. Hill MD (2014) Stroke and diabetes mellitus. Handb Clin Neurol 126:167–174. https://doi.org/10.1016/B978-0-444-53480-4.00012-6

16. Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. (2021) Risk of Systemic Adverse Deseases after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology; 128(3):417-424. https://doi.org/10.1016/j.ophtha.2020.07.062

17. Wang W, Zhang X. (2014) Systemic adverse deseases after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PLoS One 9(10):e109744. https://doi.org/10.1371/journal.pone.0109744

18. Ngo Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, Bejan-Angoulvant T (2021) Cardiovascular Adverse Deseases With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Ophthalmol. 15;139(6):1–11. https://doi.org/ 10.1001/jamaophthalmol.2021